July 16 (Reuters) - A U.S. federal judge rejected Swiss drugmaker Novartis' (NOVN.S), opens new tab request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

Novartis is no stranger to investigations into its marketing practices. The latest? U.S. federal prosecutors are sniffing around the company’s second-best-selling drug. In September, Novartis received ...

Novartis NVS recently received an unfavorable ruling from the U.S. District Court for the District of Delaware regarding the validity of a patent covering its flagship product, Entresto. This patent, ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...